Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial-intelligence-driven ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

Despite billions poured into research, new medicines still typically take a decade or more to develop.

Becco Management sold the 1 million-square-foot campus in Libertyville, Illinois, for $35 million, a discount to its ...